 |
|
|
| |
Reverse transcriptase connection-domain mutations were not associated with virologic failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (Week 96 analysis)
|
| |
| |
Reported by Jules Levin
Presented at the International Workshop on HIV & Hepatitis Virus
Drug Resistance and Curative Strategies
Sitges, Spain, 5-9 June 2012
Laurence Rimsky,1 Veerle Van Eygen,1 Johan Vingerhoets,1 Erik Leijskens,1 Gaston Picchio2
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Research & Development LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
